ZOLEDRONIC ACID - Z SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Disponible desde:

SANDOZ CANADA INCORPORATED

Código ATC:

M05BA08

Designación común internacional (DCI):

ZOLEDRONIC ACID

Dosis:

4MG

formulario farmacéutico:

SOLUTION

Composición:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Vía de administración:

INTRAVENOUS

Unidades en paquete:

5ML

tipo de receta:

Prescription

Área terapéutica:

BONE RESORPTION INHIBITORS

Resumen del producto:

Active ingredient group (AIG) number: 0141761002; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2013-02-15

Ficha técnica

_Zoledronic Acid – Z _
_ _
_Page 1 of 51 _
PRODUCT MONOGRAPH
PR
ZOLEDRONIC ACID - Z
(Zoledronic acid for Injection)
4 mg zoledronic acid/5 mL incorporated as the monohydrate for
intravenous infusion
Bone Metabolism Regulator
Sandoz Canada Inc.
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
Date of Revision:
July 21, 2017
Control No. : 206684
_Zoledronic Acid – Z _
_ _
_Page 2 of 51 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT
INFORMATION....................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
.............................................................................................................
12
DRUG INTERACTIONS
.............................................................................................................
20
DOSAGE AND ADMINISTRATION
.........................................................................................
20
OVERDOSAGE
............................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
25
STORAGE AND STABILITY
.....................................................................................................
29
DOSAGE FORMS, COMPOSITION AND
PACKAGING......................................................... 29
PART II: SCIENTIFIC INFORMATION
...............................................................................
30
PHARMACEUTICAL INFORMATION
..................................................